What the buyer wrote
MDC's current imaging capabilities are limited to PET and CT, which restricts us to PET based tracers. While PET imaging is a powerful tool, it cannot accommodate a growing range of radioisotopes that are increasingly relevant in theranostic applications. These include lead 203, lead 212, lutetium 177, and actinium 225, which are essential for both diagnostic and therapeutic purposes. This limitation has become more pronounced as clinical and research interest in SPECT and CT imaging continues to grow. SPECT imaging enables biodistribution studies for isotopes that PET cannot support. This opens up new possibilities for molecular imaging and expands our ability to respond to evolving scienti…
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Details
- What the buyer calls it
- Molecubes Preclinical SPECT Imager
- How they are buying
- Given to one supplier, no competitionNobody else was asked, and the buyer has to be able to justify that.
- Work starts
- 1 Oct 2025
- Work ends
- 2 Jan 2027
- Where
- in the North West
Who the buyer named
Ms Laura Hough was the named contact on this notice.